# 510(k) Summary 807.92(c)

SPONSOR Company Name:

807.92(a)(1)

Prodigy Diabetes LLC

Company Address:

9300 Harris Corners Parkway Suite 450 Charlotte, NC 28269

Telephone: Fax: Contact Person:

704-285-6400 Fax: 704-285-6475 Rick Admani

Summary Preparation Date: October 14, 2010

# DEVICE NAME

Trade Name:   
Common/Usual Name:   
Classification Name:   
Regulation Number:   
Product Code:   
Device Class:   
Panel:

807.92(a)(2) Prodigy® Diabetes Management Software Blood Glucose Meter and Data Management System, Test, Blood Glucose, Over the Counter 862.1345 NBW;JQP II Clinical Chemistry

# PREDICATE DEVICE

807.92(a)(3)

Legally Marketed Equivalent Device Cecton Dickinson BD™M Diabetes Software Product 5K1032 29

# DEVICE DESCRIPTION

807.92(a)(4)

The Prodigy® Diabetes Management Software is a moderate level of concern software management system that allows the user an additional method of tracking their blood glucose level. The software allows for data transfer from a Prodigy Blood Glucose Monitor via a USB cable. The Prodigy® Diabetes Management Software is designed to operate on the patient's PC with Microsoft SQL Server 2005 or later operating system. Prodigy® Diabetes Care LLC website will provide a link to download the Microsoft SQL Server 2005.

The Prodigy® Diabetes Management Software is indicated for use as a data management tool for the acceptance, transfer, display, storage, processing (e.g., averaging). Reporting, and printing of patient blood glucose monitoring data.

The Prodigy® Diabetes Management Software is indicated for use with the Prodigy Blood Glucose Monitoring Systems only.

COMPARISON OF TECHNICAL CHARACTERISTICS 807.92(a)(6)   

<table><tr><td></td><td colspan="3" rowspan="1">Parameters</td></tr><tr><td></td><td colspan="1" rowspan="1">Parameters</td><td colspan="1" rowspan="1">Prodigy DiabetesManagement Software</td><td colspan="1" rowspan="1">Becton Dickinson DiabetesSoftware</td></tr><tr><td></td><td colspan="1" rowspan="1">510(k) Number:</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">K023219</td></tr><tr><td></td><td colspan="1" rowspan="1">Indications for Use</td><td colspan="1" rowspan="1">The Prodigy® DiabetesManagement Software isindicated for use as a datamanagement tool for theacceptance, transfer,display, storage, processing(e.g., averaging). Reporting,and printing of patientblood glucose monitoringdata.The Prodigy® DiabetesManagement Software isindicated for use with theProdigy Blood GlucoseMonitoring Systems only.</td><td colspan="1" rowspan="1">The BDTM DiabetesSoftware is intended for useas a data management toolfor acceptance, transfer,display, storage, processing(e.g. averaging), reporting,and printing for patientblood glucose monitoringdata.The device is intended foruse with the BD BloodGlucose MonitoringSystems only.</td></tr><tr><td colspan="2" rowspan="1">Download blood glucosemeter readings via USBinterface cable</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="2" rowspan="1">Electronic Log Book</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="2" rowspan="1">Create User Profile</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="2" rowspan="1">Create reports</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Create trending graphs</td><td colspan="1" rowspan="1">Yes.</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="2" rowspan="1">Option for printingreports</td><td colspan="1" rowspan="1">Yes.</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="2" rowspan="1">Features of the SoftwareSystem</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="2" rowspan="1">Set Target - target bloodglucose range</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="2" rowspan="1">Average reading for eachmeal over the past several</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">weeks</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Over -the-Counter</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr></table>

# SUBSTATIAL EQUIVALENCE

The software feature comparisons above of the BDTM Diabetes Software and the Prodigy® Diabetes Management Software demonstrate that the Prodigy® software system is substantially equivalent to the predicate device based on the following similarities:

Patient can create personal and meter profiles   
Patient can import data from the Prodigy Blood Glucose Meter,   
Patient can set blood glucose target ranges and personal schedule,   
Patient has a Log book to view recorded data,   
Patient can retrieve reports and trending graphs, and   
Patient can print Trend graphs and reports

# PERFORMANCE DATA

Aclinical usability study was performed to veriy ease ofuse and label comprehension.

# CONCLUSION

807.92(b)(3)

Based on the product comparison and the Human Factor Study Prodigy® Diabetes Care LLC concludes that the Prodigy® Diabetes Management Software does not raise any new issues concerning safety and effectiveness.

Prodigy Diabetes Care, LLC. c/o Smith Associates E.J. Smith, Consultant 1468 Harwell Avenue, Crofton, MD 21114

Re: k103115 Trade/Device Name: Prodigy Diabetes Management Software Regulation Number: 21 CFR 862.1345 Regulation Name:Glucose test system. Regulatory Class: II Product Code: NBW, JQP Dated: September 28, 2011 Received: September 28, 2011

Dear Mr. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class [I (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, F'DA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Pari 820).

Page 2-

If you desie speciic advice for your device on our labeling regulation (21 CFR Par 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's ('s) Division of Postmarket Surveillance a (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-ree number (800) 638-2041or 3019- 5680or at its Internetaddress http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/fa7a0445752188359a4e68b043f69aada7076a737e107a714eafdee4bbecc3ae.jpg)

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

510(k) Number(if known):103

# Indications for Use

Device Name: Prodigy $\otimes$ Diabetes Management Software

Indications for Use:

The Prodigy® Diabetes Management Software is intended for use as a data management trcta tans isply orae, psin aveig rti printing of patient blood glucose monitoring data.

The device is intended for use with the Prodigy® Blood Glucose Monitoring Systems only.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Qutl Chal

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety